Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence

Inclusion Criteria: Disease-related criteria: * persistent urinary incontinence \>= 12 months following radical prostatectomy for prostate adenocarcinoma * presenting an indication for surgical insertion of a medical device * 24h PAD test \> 100 g per day * controlled prostate adenocarcinoma, with PSA ≤ 1 ng/ml Population-related criteria: * male subjects aged 18 years and over * having provided free, informed written consent to take part in the study * patients independent and able to use the collar without difficulty and able to manage an artificial sphincter * Patient able to understand and sign the consent form and to complete questionnaires * Patient without mental impairment * Patients belonging to or covered by Social Security. Exclusion Criteria: Disease-related criteria: * Documented neurological bladder or history of neurological disease liable to interfere with urinary symptoms. * Presence of urethral anastomotic stenosis preventing passage of the fiberscope at the initial endoscopy * Severe symptomatic hyperactive or hypoactive bladder not controlled by drug therapy * Severe constitutional haemorrhagic disease or haemophilia * Patients presenting urinary infection not controlled * Patients presenting severe renal failure and obstructive pathologies of the upper urinary tract with severe renal failure. * Patients presenting deep immune deficiency * Patient presenting recto-urethral fistula * Patient with tumor of bladder * Patient having bladder stones with failure of bladder stone treatment Criteria related to incontinence treatment: * Allergy to any of the components of the medical devices * History of surgery to insert a medical device for treatment of incontinence (e.g. artificial sphincter, suburethral strap, continence balloons, etc.) * History of periurethral injection of filling agents * Inability to use either of the study devices * Drug treatment: duloxetine or any treatment likely to modify continence results * Not receiving and not likely to receive radiotherapy at any time throughout the 12-month follow-up period Population-related criteria * Foreseeable unavailability during the study . Patient deprived of liberty by administrative or judicial decision or under legal guardianship * Participation in another clinical trial in the 3 months preceding the initial visit